RRM1 and small cell lung carcinoma: Taken together, our findings suggest that RRM1 could be a potential target for the development of new molecular targeting therapies for SCLC, whereas the metabolite profile could be used as a biomarker for assessing the sensitivity and response to RRM1 therapy.